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Introduction: 49 
The vitamin K family is comprised of a group of fat-soluble molecules that share the 2-methyl-1,4-50 
naphthoquinone (3-) groups. Vitamin K exists in 3 main forms, K1 and K2 which are the natural 51 
form, and K3 or menadione which is the synthetic form of the vitamin [1]. Vitamin K1, also known 52 
as phylloquinone, is found in vegetables, while vitamin K2, also known as menaquinone, is found in 53 
fermented food or produced by the intestinal microbiota. Vitamin K1 can be converted into vitamin 54 
K2.   Two mechanisms of action of vitamin K have been described to date. It is an essential cofactor 55 
for the function of the enzyme γ‐glutamyl carboxylase, and it acts as a ligand of the steroid and 56 
xenobiotic receptor (SXR) and pregnane X receptor (PXR, murine ortholog) [2]. 57 
Vitamin K-dependent proteins (VKDPs) play important roles in human physiology and can be an 58 
important link between the bone and the vasculature. This link becomes particularly important in 59 
patients with chronic kidney disease (CKD) who have a high prevalence of both mineral bone 60 
disorders (MBD) and vascular calcification (VC) [3] and whose primary cause of death is 61 
cardiovascular disease. Osteocalcin (OCN) is a VKDP known to be involved in bone mineralization, 62 
while Matrix GLA protein (MGP) is a known VC inhibitor whose deficiency is associated with 63 
increased risk for VC in CKD. New VKDPs have been discovered, and they have been found to play 64 
important roles in various cancers and their therapies.  65 
While many questions have been answered, many more remain regarding the roles of the VKDPs in 66 
bone and vascular physiology. This review will discuss the roles of VKDPs and vitamin K in different 67 
pathologies.  68 
 69 
Vitamin K Dependent Protein (VKDPs) 70 
Vitamin K is an essential cofactor required for the activation of the gamma glutamyl carboxylase 71 
which converts glutamic acid to γ-glutamic acid residues. There are several vitamin K dependent 72 
proteins (VKDPs) [4]. These include the coagulation factors proteins C, S, M, Z, factors VII, IX, X 73 
and prothrombin. VKDPs also include Bone Gla Protein (BGP, or osteocalcin), Matrix Gla Protein 74 
(MGP), Gas6 (Growth Arrest-Specific 6 Protein), GRP (Gla Rich Protein) and Periostin. VKDPs play 75 
established roles in coagulation, in bone health and in cardiovascular health.  76 
 77 
Bone Gla Protein (BGP): Beyond Skeletal Health  78 
BGP or osteocalcin is the most abundant protein in bone. It is mainly secreted by osteoblasts, with a 79 
smaller amount secreted by chondrocytes[5]. BGP undergoes three carboxylation events to be 80 
transformed from the undercarboxylated form into the fully functional form. These carboxylation 81 
events require vitamin K as a cofactor[6]. Several mechanisms describing the BGPs role in bone 82 
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physiology have been proposed, including the inhibition of bone mineralization[7], the regulation of 83 
the rate of mineral maturation[8], and the formation of a complex between bone matrix and collagen 84 
in order to increase bone toughness[9]. However, none of these mechanisms are fully proven.  85 
 86 
More recently, the relationship between BGP and glucose metabolism has been elucidated. In this 87 
role, BGP is thought to be released into the circulation and to exert an action similar to a hormonal 88 
effect[10]. This shed light into the peripheral functions of BGP and led to increased interest in this 89 
protein, therefore uncovering a wide range of functions.  90 
 91 
The role of BGP in glucose metabolism and insulin signaling was first discovered by Lee et al[11] 92 
whose experiments showed that BGP knockout mice develop glucose intolerance, insulin resistance, 93 
and increased adipose tissue. The circulating form of BGP exerting the metabolic effects is mostly 94 
the undercarboxylated form (ucBGP). By binding to the receptor Gprc6a, in animals ucBGP acts on 95 
the pancreatic beta cells [10]. The influence of BGP on insulin sensitivity may be mediated via its 96 
effect on adiponectin, independent of insulin secretion[11]. Human studies have not shown this 97 
metabolic effect, however. When Basu et. al administered insulin to seven diabetic and seven non-98 
diabetic patients and assessed the association with bone turnover markers, the change in the insulin 99 
levels did not influence BGP and ucBGP levels[12]. In humans, BGP also acts on Leydig cells thereby 100 
affecting the reproductive function of males[13].  101 
 102 
Beyond the metabolic functions, BGP is involved in vascular calcification (VC) modulation through 103 
its effect on adiponectin[11]. Adiponectin inhibits osteoblastic differentiation of vascular smooth 104 
muscle cells, therefore protecting against VC[14]. In apolipoprotein E-deficient mice, daily injections 105 
of BGP for 12 weeks resulted in endothelium protection from atherosclerosis, but whether this was 106 
also mediated by the concomitant improvement in glucose metabolism is unknown[15]. Similarly, 107 
diabetic rats given daily injections of BGP had an improvement in arterial stiffness as assessed by 108 
pulse wave velocity[16].  109 
The role of BGP in modulating and possibly preventing VC was confirmed in humans. BGP may 110 
exert this effect through its interaction with adiponectin, as seen by Bacchetta et al. when they found 111 
a significant association between BGP and adiponectin in CKD patients[17].  112 
In human cardiovascular tissues, BGP was found in higher concentrations in calcified aorta and 113 
valves as compared to non-calcified tissue[18]. Fusaro et al. found lower BGP levels in patients with 114 
aortic and iliac calcifications as compared to patients without calcifications[19]. In men aged 51-85 115 
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years old in the MINOS study, higher total BGP levels were associated with slower progression of 116 
abdominal aortic calcification after a 10 year follow up[20].  117 
 118 
In contrast to the above findings, in the Study of Osteoporotic Fractures (SOF) which enrolled 363 119 
elderly women, total BGP levels were not associated with abdominal aortic calcification[21].  120 
Moreover, in a meta-analysis of 46 clinical studies evaluating the relationship between BGP and VC, 121 
no definite associations could be found between the different forms of BGP (ucBGP, cBGP and total 122 
BGP) and VC. However, sound physiological conclusions cannot be drawn based on these findings. 123 
In fact, 44% of the included studies did not adjust for confounding variables and the BGP forms were 124 
measured using different assays in the different studies[22]. Moreover, BGP displays a circadian 125 
rhythm with levels falling in the morning and reaching the peak in the evening [23]. Therefore, the 126 
timing of blood draws may impact the results of the studies. It is also important to note that BGP is 127 
cleared by the kidneys[24]. Therefore any decline in renal function results in an elevation in BGP 128 
levels [24]. This is particularly notable when the glomerular filtration rate drops below 20 ml/min[24] 129 
. Additionally, based on the aforementioned studies, gender appears to be a confounding factor with 130 
the effects of BGP being differential between males and females. Vitamin K levels are obvious 131 
confounders. Moreover, menopausal status, adipose tissue, diabetic status are all expected to be 132 
confounders as well [25]. If we want studies that more accurately unravel the effect of BGP on the 133 
vasculature, we should standardize our BGP serum measurements and understand more carefully the 134 
confounders that should be accounted for. 135 
 136 
Matrix Gla Protein (MGP): Beyond Cardiovascular Health  137 
MGP is a 14 kDa vitamin K-dependent protein which after carboxylation can have up to 5 gamma-138 
carboxyglutamic acid residues [26]. In addition to gamma-carboxylation, MGP requires post-139 
translational serine phosphorylation. Phosphorylation occurs at 3 serine residues via the enzyme 140 
casein kinase[26, 27]. Phosphorylation regulates the protein secretion into the extracellular 141 
environment[26]. Based on the degree of carboxylation and phosphorylation, multiple forms of MGP 142 
can be found in the circulation and the extracellular matrix (Figure 1). MGP is released from vascular 143 
smooth muscle cells and chondrocytes [28]. It was the first calcification inhibitor to be 144 
characterized[28].  The exact mechanism through which MGP inhibits VC is not completely 145 
understood. However, the carboxylated active form of MGP is believed 1) to bind to calcification 146 
crystals in blood vessels forming vesicles and apoptotic bodies, 2) to directly prevent calcium 147 
phosphate precipitation, and 3) to prevent the trans-differentiation of vascular smooth muscles cells 148 
into an osteogenic phenotype [26, 29].  149 
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The different forms of MGP can be used as a biomarker of vitamin K deficiency[30]. Vitamin K 150 
deficiency in CKD leads to a decrease in the levels of the phosphorylated-carboxylated MGP (p-151 
cMGP) and a rise in the levels of dephosphorylated undercarboxylated MGP (dp-ucMGP) [31]. 152 
Plasma dp-ucMGP levels increase as CKD advances with the highest levels found in CKD stage 153 
5[31]. Plasma dp-ucMGP is positively associated with VC and might be utilized as an early marker 154 
for vascular calcification in CKD patients[30, 31]. 155 
 156 
Beyond the well-established effects of MGP in VC[32] studies also suggest that it has a role in skeletal 157 
health. Mice deficient in MGP develop diffuse VC as well as inappropriate calcification of the growth 158 
plate[28]. Mice overexpressing Mgp in osteoblasts have a decrease in bone mineralization 159 
particularly in the tooth dentin and cementum. Thus, MGP affects bone mineralization[33]. MGP 160 
interacts with both osteoblasts and osteoclasts. Phosphate regulates MGP expression in osteoblast 161 
cultures via the ERK1/2-Fra-1 pathway [34]. Via Src/Rac1 signaling, MGP modulates 162 
osteoclastogenesis; MGP depletion favors while MGP excess inhibits osteoclast differentiation [35]. 163 
 164 
In clinical studies, homozygosity of the MGP rs1800802 minor allele, but not total serum MGP levels 165 
was associated with 0.56 times lower prevalence of hand osteoarthritis compared with having ≥ 1 166 
major allele at this locus (95% CI 0.32-0.99, p<0.05), suggesting a role for MGP in osteoarthritis[36]. 167 
Among 145 participants in the European Vertebral Osteoporosis Study, men with the homozygous 168 
MGP-7AA polymorphism had significantly more femoral bone loss as compared to those with 169 
genotypes -7GG and -7GA [37]. Those homozygous for MGP 83Ala-Ala had significantly more 170 
femoral neck loss as well as a greater tendency to vertebral fractures as compared to those with the 171 
genotypes 83Thr-Thr and 83Thr-Ala. A decrease in BMD was observed only in MGP-7AA and 172 
MGP 83Ala-Ala genotypes. These associations were not found in the 151 women who participated 173 
in the study possibly because 94% of the women were post-menopausal and had independent post-174 
menopausal bone loss that could have confounded the effect of the MGP polymorphisms.  175 
The effect of MGP on fractures and bone density was similarly seen following kidney transplantation. 176 
Evenepoel et al. evaluated vitamin K deficiency as measured by dp-ucMGPlevels in 468 de novo 177 
kidney transplant recipients. The patients with the highest tertile of dp-ucMGPlevels had lower bone 178 
mineral density and had higher incident fractures independently of common fracture determinants 179 
(HR 2.21; 95% CI, 1.00 to 4.91; p < 0.05) [38].  180 
 181 
Studies evaluating the relationship between renal clearance and MGP levels are rare. In 842 182 
outpatients with stable cardiovascular disease and a mean GFR of 76±23 mL/min, each 10 mL/ min 183 
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lower GFR was associated with a 79 nM lower ucMGP serum level (p < 0.001), and a 0.1 mg/L 184 
higher cystatin-C was associated with a 39 nM lower ucMGP serum levels (p < 0.001) in multivariate 185 
adjusted models [39]. However, when Rennenberg et al. looked at this association, they found no 186 
significant correlations between total MGP levels in renal arterial and venous blood and renal 187 
clearance of 90 patients with hypertension[40]. It is important to note however that none of the 188 
patients in this cohort had a GFR <26 mL/min[40]. A relationship between MGP levels and renal 189 
clearance at a GFR <26 mL/min is therefore still possible. 190 
 191 
 192 
Vitamin K as Ligand of Nuclear Receptors  193 
Vitamin K can act as ligand of the nuclear Steroid and Xenobiotic Receptor (SXR) and its murine 194 
ortholog, Pregnane X Receptor (PXR)[41]. SXR/PXR is present in different tissues, including 195 
osteoblastic cell lines [42, 43]. The presence of SXR/PXR in osteoblastic tissue is important as it 196 
could be the pathway through which vitamin K improves bone health [44].  197 
Transcriptome analysis has revealed a number of bone-related genes which are involved in the 198 
vitamin K-SXR pathway. These include tsukushi and matrilin-2, which are involved in collagen and 199 
extracellular matrix assembly [45, 46]. In sarcoma cells, vitamin K up-regulates osteoblastic bone 200 
markers [43]. SXR/PXR knockout mice have increased bone resorption and decreased bone 201 
formation [47]. 202 
 203 
SXR is additionally involved in bone metabolism via its effect on vitamin D metabolism. In this role, 204 
SXR activation can have two effects.  SXR activation by some drugs can lead to CYP3A4 expression 205 
(exerting 24- and 25-hydroxylase activity) and resultant vitamin D metabolism and deficiency. SXR 206 
activation can also lead to inhibition of CYP24A1 (24-hydroxylase activity) in the kidney therefore 207 
increasing 1,25(OH)D levels [48]. These data suggest that SXR/PXR is another pathway through 208 
which vitamin K is involved in bone homeostasis. 209 
 210 
Vitamin K in Chronic Kidney Disease (CKD) 211 
The western diet does not provide enough vitamin K to activate VKDPs in all tissues[49]. This 212 
deficiency is more pronounced in adults over the age of 40. Patients with CKD have even greater 213 
rates of vitamin K deficiency as compared to the general population. The number of CKD patients 214 
who have vitamin K deficiency reaches 70-90% of that population [50, 51, 52] (Table 1). Poor oral 215 
intake of vitamin K is the main cause of deficiency [50, 53]. When compared to healthy individuals, 216 
the vitamin K intake of HD patients is particularly low on days of dialysis and the weekend[54]. The 217 
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use of phosphorus binders in the dialysis population contributes to vitamin K deficiency as well [55]. 218 
Being lipophilic, vitamin K should not be removed via dialysis. However, studies to validate this 219 
hypothesis are needed, because serum levels of 25(OH)-vitamin D, another lipophilic molecule, 220 
decreased in patients who were switched from conventional hemodialysis to online hemodiafiltration 221 
[56]. 222 
 223 
There are known implications of vitamin K deficiency in population-based studies and in kidney 224 
disease patients [57, 58]. In the Rotterdam study of 7983 men and women over the age of 55, intake 225 
of menaquinone protected against incident coronary heart disease (RR of highest tertile of 226 
menaquinone intake as compared to lowest tertile = 0.59, p=0.007), and against coronary heart disease 227 
related mortality (RR of highest tertile of menaquinone intake as compared to lowest tertile = 0.43, 228 
p=0.005). Additionally, the odds ratio of severe aortic calcification was significantly lower in the 229 
patients with the highest intake of menaquinone intake as compared to those with lowest intake (OR 230 
0.48, p <0.001) [59]. In the VIKI study, a cohort of 387 dialysis patients, 35.4% of patients had 231 
menaquinone-7 deficiency, 23.5% of patients had vitamin K1 deficiency and 14.5% of patients had 232 
menquinone-4 deficiency [57]. Patients with menaquinone-4 deficiency had significantly higher 233 
aortic calcification (10.6% versus 1.3%, p = 0.01). Menaquinone-7 deficiency was associated with 234 
significantly higher iliac calcifications (41% versus 28.2%, p = 0.009) [57]. 235 
 236 
There is no gold-standard for the measurement of vitamin K levels and there is a lack in 237 
standardization. Instead, functional deficiency of vitamin K is used as a surrogate of vitamin K status 238 
in individuals. Vitamin K deficiency in CKD leads to a decrease in the levels of active MGP, a rise 239 
in the levels of dp-ucMGP, as well as a rise in the levels of ucBGP[37]. Plasma dp-ucMGP levels 240 
increase as CKD advances with highest levels being in CKD stage 5[38].  A dp-ucMGP level of >500 241 
pmol/L, ucBGP>4.5 ng/mL[59] or protein induced by vitamin K absence-II (PIVKA-II) >2 nM/L  242 
are indicative of vitamin K deficiency [30, 60].  243 
 244 
In 53 dialysis patients, vitamin K2 supplementation resulted in a dose dependent decrease in 245 
functional vitamin K deficiency. After a 6-week supplementation regimen, dp-ucMGP levels were 246 
reduced 77% and 93% in the groups receiving daily oral administration of 135 μg and 360 μg of K2, 247 
respectively[61]. In 200 HD patients receiving vitamin K2 at dose of 360, 720 or 1080 µg thrice 248 
weekly for 8 weeks, dp-uc-MGP levels decreased by 17%, 33% and 46% respectively[62]. Several 249 
studies show the same pattern (Table 2). 250 
 251 
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Although kidney transplantation is associated with an improvement in vitamin K levels[55],  a 252 
deficiency in vitamin K was still found in up to 91% of kidney transplant patients.  This deficiency 253 
may persist as long as 188 months post transplantation[38, 63]. Moreover, in at least one study, 254 
vitamin K deficiency in kidney transplant patients was associated with an almost 3 times increase in 255 
all-cause mortality [63]. 256 
 257 
How Current therapy of MBD in CKD Influences Vitamin K levels and VKDPs 258 
While MBD derangements contribute to renal osteodystrophy and to VC in CKD [64], treatments of 259 
MBD have not been sufficiently successful at reversing VC, improving cardiovascular events or 260 
decreasing mortality. We hypothesize that this might be partly explained by the negative impact of 261 
some of the MBD treatments on vitamin K levels. One such treatment is sevelamer. Sevelamer is 262 
thought to bind fat-soluble vitamins [65, 66]. Since vitamin K is a fat-soluble vitamin, Jansz et al. 263 
assessed the impact of sevelamer on vitamin K in patients who received a kidney transplantation. 264 
They found that sevelamer is associated with higher dpu-cMGP levels reflecting vitamin K deficiency 265 
[55]. This finding points to the possible need of giving vitamin K supplements to patients treated with 266 
sevelamer, but this approach should first be substantiated by a specific study. 267 
 268 
However, some MBD treatments are associated with improvements in VKDPs. In an analysis of the 269 
VIKI study [57], the use of calcimimetics and vitamin D analogs was associated with higher levels 270 
of BGP. Calcimimetic use was also associated with higher levels of total MGP [19]. Therefore, this 271 
data suggests that calcimimetics and vitamin D analogs can help preserve or improve the activity of 272 
VKDPs. 273 
 274 
VKDPs Beyond Bone and Vascular Health  275 
 276 
Growth Arrest-Specific Protein 6 (Gas6) 277 
Gas6 is a gamma-carboxyglutamic acid (Gla) domain-containing protein, member of the VKDPs 278 
family, which is present in several different tissues (e.g. vascular endothelium, kidney, heart, and the 279 
bone marrow). It is a ligand for the TAM (Tyro3-Axl-Mer) receptor family [67] and is thought to be 280 
involved in the stimulation of cell proliferation, migration and apoptosis [68, 69]. 281 
Gas6 and protein S are two homologous secreted proteins depending on vitamin K for a wide range 282 
of their biological functions. A discrete subset of these functions is mediated through their binding to 283 
and activation of the receptor tyrosine kinases Axl, Sky and Mer; in particular, the vitamin K-284 
dependent protein Gas6 activates receptor tyrosine kinases of the Axl family [69].  285 
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A hallmark of the Gas6-Axl system is the unique ability of both Gas6 and protein S to tether their 286 
non receptor-binding regions to the negatively charged membranes of apoptotic cells. A relevant 287 
amount of evidence suggests that the Gas6-Axl system is able to regulate cell survival, proliferation, 288 
migration, adhesion and phagocytosis. Consequently, an altered expression, or a compromised 289 
activity of its components have been detected in a variety of diseases, including different cancer types. 290 
Moreover, Axl overactivation can equally occur without ligand binding, which has implications for 291 
tumorigenesis. [70] 292 
Upregulation of Gas6 has been described in different malignancies [71], and an increased expression 293 
of either Gas6 or TAM receptor proved to be predictive of poor prognosis[72]. A number of animal 294 
studies highlighted the role of Gas6 in the processes of carcinogenesis [71, 72, 73], while clinical 295 
studies are rarer, but ultimately show consistent findings. Ovarian cancer samples from 90 patients 296 
had significantly higher expression of Gas6 and Axl as compared to normal ovarian tissue [73], RNA 297 
PCR from 42 glioblastoma frozen sections demonstrated that Gas6 and Axl are overexpressed both 298 
in the tumoral, as well as in the surrounding vascular, tissue [74]. Furthermore, glioblastoma patients 299 
whose tumors expressed higher Gas6 and Axl levels had significantly higher risk of tumor relapse as 300 
well as shorter time to relapse [74]. A similar observation has been reported in osteosarcoma; indeed, 301 
in 62 osteosarcoma patients, Axl was highly expressed in 43.5% of the cases, characterized by a 302 
significantly higher rate of recurrence, lung metastases, as well as a lower survival [75]. Gas6-Axl is 303 
also important as mechanisms of resistance to anticancer therapy; indeed, resistance to tyrosine kinase 304 
inhibitors in non-small cell cancer and renal cell carcinoma (RCC) was found to be driven by Axl 305 
[76].  306 
As far as RCC, the Axl protein proved to be highly expressed in clear cell RCC cells deficient in 307 
functional von Hippel-Lindau (VHL) protein, a tumor suppressor gene often inactivated in ccRCC. 308 
VHL reconstituted cells expressed decreased levels of Axl protein, but not Axl mRNA, suggesting 309 
that VHL may regulate Axl expression. Furthermore, Gas6-mediated activation of Axl in ccRCC cells 310 
resulted in Axl phosphorylation, receptor down-regulation, decreased cell-viability, as well as 311 
migratory capacity, whilst no effects of the Gas6/Axl system could be detected on invasion. 312 
Moreover, in ccRCC tumor tissues, Axl was phosphorylated and Gas6 gamma-carboxylated, 313 
suggesting these molecules to be active in vivo. [77] 314 
All the above has practical therapeutic implications, as targeting the Gas6-Axl pathway through the 315 
multikinase inhibitor cabozantinib proved to be an active treatment option for metastatic RCC 316 
patients progressing on standard antiangiogenic therapy [78].   317 
 318 
Periostin 319 
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Periostin is another member of the VKDP family. Similar to other VKDPs, the carboxylation of 320 
periostin is dependent on vitamin K. However, it is unknown how the carboxylation status of periostin 321 
influences its functions in different tissues. Periostin is an extracellular matrix protein that binds 322 
integrins playing a role in cellular adhesion and migration[79]. It plays a role in collagen assembly in 323 
several tissues and is upregulated when tissues are subjected to stress[79-81]. Following cardiac 324 
injury, periostin is expressed in cardiac myofibroblasts and vascular smooth muscle cells contributing 325 
to a profibrotic phenotype[81-83]. Similar to other VKDPs, periostin has also been found in many 326 
cancers [84-86]. Periostin induces tumor angiogenesis[84, 85] and lymphangiogenesis [85], and its 327 
association with cancer confers a worse prognosis to patients[85]. The role of periostin in breast 328 
cancer has been described. Periostin is expressed in invasive ductal carcinoma cells [87]. Its 329 
expression increases with the cancer grade, suggesting that periostin may play a role in cancer 330 
progression[88]. Periostin can also serve as marker of breast cancer metastasis. Human breast cancer 331 
exosomes contain periostin. Further, periostin enriched exosomes were found in patients with lymph 332 
node metastasis as compared to those with localized disease[89]. Finally, periostin may have a role 333 
in breast cancer prognostication. In 259 breast cancer patients who underwent surgical and radiation 334 
therapy, local recurrence-free survival, distant metastasis-free survival and overall survival were 335 
significantly lower in the patients whose tumors expressed periostin as compared to those whose 336 
tumors were negative for periostin [90].  337 
 338 
 339 
Gla-Rich Protein (GRP) 340 
 341 
GRP is one of the newest members of the VKDP family. Its name derives from the large amount of 342 
Gla residues, which comprise 22% of its composition[91], and which make it the VKDP with the 343 
highest concentration of Gla residues. Since its discovery, GRP has been found to have a role as an 344 
anti-inflammatory protein[92]. In vivo, it prevents osteoarthritis progression[93]. It additionally plays 345 
a role in mineralization. In both animal models and in humans, GRP has been found to colocalize 346 
with mineral deposits at sites of calcification[94]. Further work demonstrates that similar to MGP, 347 
GRP in its carboxylated but not in its undercarboxylated form is a calcification inhibitor [95]. 348 
Although GRP role in cancer is less established as compared to other VKDPs, there is growing 349 
interest surrounding this protein. The undercarboxylated form as compared to the carboxylated form 350 
of GRP is found in more abundance in skin and breast cancer cells, particularly in microcalcifications 351 
associated with these tumors [96]. Therefore, GRP may be involved in cancer-related calcifications 352 
and as such may prove to be a therapeutic target for some types of cancer. 353 
 354 
  
12 
Vitamin K in Cancer 355 
Several VKDPs are involved in tumorigenesis[71, 84, 85] (Table 3). Vitamin K2 administration in 356 
vivo inhibits the cellular proliferation of several cancers [96, 97]. This led to a number of studies 357 
investigating the role of vitamin K intake and supplementation in preventing cancer development, 358 
progression and recurrence. In the European Prospective Investigation into  359 
Cancer and Nutrition-Heidelberg cohort study which included 24,340 cancer-free participants 360 
followed up for 10 years, there was a significant  inverse association between vitamin K2 intake and 361 
cancer mortality, but not cancer incidence[98]. Similarly, in the Prevención con Dieta Mediterránea 362 
study, which enrolled 7216 participants followed up for a median of 4.8 years, subjects who increased 363 
their dietary intake of both vitamin K1 and K2 had decreased cancer incidence[99].  364 
The undercarboxylated form of prothrombin (PIVKAII), a VKDP, is upregulated in hepatocellular 365 
carcinoma (HCC) [100]. Vitamin K2 supplementation in patients who underwent curative 366 
hepatectomy or radiofrequency ablation for HCC suppressed HCC recurrence, though this effect 367 
did not reach statistical significance in any of these studies[101, 102]. In contrast, 45 mg per day 368 
of vitamin K2 supplementation resulted in significantly lower risk of HCC development in 21 369 
women who had viral cirrhosis as compared to 19 women with viral cirrhosis who did not receive 370 
supplementation[103]. This suggests that vitamin K2 may play a role in preventing the development 371 
of HCC in high risk patients. Overall, the association and the relationship of vitamin K with cancer 372 
is still uncertain and under investigation. Further studies are needed to define this role of vitamin 373 
K. 374 
 375 
Conclusion  376 
Substantial research has made it clear that VKDPs or Vitamin-K related pathways can be used in the 377 
future to diagnose, treat and prognosticate a number of health conditions. There are still more vitamin 378 
K-related roles to be uncovered and which will further our understanding of the physiological and 379 
pathological importance of vitamin K status. It will also prove important to recognize the differential 380 
actions of vitamin K1 and vitamin K2, and to develop standardized techniques that can directly 381 
measure vitamin K levels instead of our current reliance on functional vitamin K status as measured 382 
by VKDPs levels [104]. This will allow to develop trials that can evaluate selective and optimal 383 
vitamin K supplementation strategies in order to further understand their effect on clinical outcomes. 384 
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TABLES AND FIGURES 654 
Table 1. Vitamin K and VKDP levels in Kidney Disease 655 
AUTHOR, YEAR NUMBER OF 
PARTICIPANTS 
KIDNEY 
DISEASE 
STAGE 
VITAMIN K FORM 
MEASURED 
% OF 
PATIENTS 
WITH 
VITAMIN K 
DEFICIENCY   
VKDP 
MEASURED 
% OF 
PATIENTS 
WITH 
MEASURED 
VKDP  
Kolheimer M., 
1997 [105] 
68 ESKD -HD Phylloquinone 33%  
 
  
Pilkey RM., 2007 
[106]  
142 ESKD Phylloquinone 29% ucBGP 93% 
Holden RM, 2008 
[52] 
21 ESKD- PD Phylloquinone 
 
24% 
 
ucBGP 60% 
Holden RM, 2010 
[107] 
172 CKD 3-5 Phylloquinone 
 
6% 
 
 
ucBGP 
 
PIVKAII 
60% 
 
97% 
Schurgers LJ, 2010 
[108] 
107 CK2-5 and 
ESKD-HD 
  dp-ucMGP 50% 
Schlieper G, 2011 
[109] 
188 ESKD-HD   PIVKA-II 
 
dp-ucMGP 
63% 
 
100% 
Cranenburg EC, 
2012 [54] 
40 ESKD-HD Phylloquinone 
 
Menaquinone 
45% 
 
100% 
PIVKAII 
 
dp-ucMGP 
82.5% 
 
100% 
Westendfeld R, 
2012 [61] 
53 ESKD-HD Menaquinone 100% PIVKAII 
 
dp-ucMGP 
92.5% 
 
100% 
Fusaro M, 2012 
[57] 
387 ESKD-HD Phylloquinone 
 
Menaquinone-4 
 
Menaquinone-7 
23.5% 
 
14.5% 
 
35.4% 
ucBGP 
 
100% 
Boxma PY, 2012 
[110] 
60 Post-
Transplantation 
  dp-ucMGP 80% 
Caluwe R, 2013 
[62] 
165 ESKD-HD   dp-ucMGP 100% 
Delanaye P, 2014 
[111] 
160 ESKD-HD   dp-ucMGP 100% 
 CA, 2015 [63] 518 Post-
Transplantation 
  dp-ucMGP 91% 
Aoun M, 2017 
[112] 
50 ESKD-HD   dp-ucMGP 100% 
 656 
 657 
 658 
  659 
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Table 2. Effect of Vitamin K supplementation on dephosphorylated-undercarboxylated MGP 660 
levels in ESKD  661 
AUTHOR, 
YEAR 
STUDY 
DESIGN 
NUMBER OF 
PARTICIPANTS 
KIDNEY 
DISEASE 
STAGE 
INTERVENTION OUTCOMES 
MEASURED 
RESULTS 
Schlieper 
G., 2011 
[109] 
Prospective 17 ESKD Vitamin K2 at 
135 μg/d for 6 
weeks 
dp-ucMGP 
level 
 Vitamin K2 supplementation resulted in a 
27% reduction in dp-ucMGP levels  
p = 0.0027 
Westenfeld 
R., 2012 
[61] 
Prospective 53 ESKD Vitamin K2 at 45, 
135, or 360 μg/d 
for 6 weeks 
dp-ucMGP 
level 
Vitamin K2 supplementation resulted in a 
dose-dependent decrease in the levels of 
dp-uc-MGP by 17.9%, 36.7%, and  
61.1% in the 45-, 135-, and 360-μg  
groups, respectively, compared with  
baseline values. p<0.005 
Caluwe R, 
2014 [62] 
Prospective 200 ESKD Vitamin K2 at 60, 
720 or 1080 µg 
thrice weekly for 
8 weeks  
  
dp-uc-MGP 
level 
  
  
Vitamin K2 resulted in a dose-dependent 
decrease in the levels of dp-uc-MGP by 
17%, 33% and 46% in the 360-, 720- and  
1080-µg groups, respectively, compared to 
baseline values.  p < 0.001 
Aoun M, 
2017 [112] 
Prospective 50 ESKD 360 μg of vitamin 
K2 
(menaquinone-7) 
for 4 weeks 
dp-uc-MGP 
level 
Vitamin K2 reduced dp-ucMGP by 86% 
P<0.05 
 662 
Table 3. Effects of VKDPs on cancer development and progression. 663 
  664 
Vitamin K dependent proteins activity may modulate cancer behavior 
Gas 6 • Angiogenesis 
• Tumor Progression 
• Higher Tumor Recurrence 
• Metastasis and Poorer Prognosis 
• Cancer Therapy Resistance 
Periostin • Angiogenesis 
• Lymphangiogenesis 
• Tumor Progression 
• Poorer Prognosis 
PIVKAII • Tumor Progression 
 665 
 666 
 667 
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Figure legends 668 
Figure 1. Different Forms of matrix Gla protein (MGP). 669 
 670 
 671 
 672 
dp-ucMGP
Casein Kinase Gamma-Glutamyl Carboxylase
5 gamma-carboxylated Gla 
residues 
3 phosphorylated serine 
residues
p-ucMGP dp-cMGP
p-cMGP
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Dear Professor Gambaro, 
 
Thank you for accepting our manuscript for submission. We appreciate the reviewer comments 
and have addressed them below.  
 
Sincerely, 
Pascale Khairallah and Maria Fusaro 
 
  
Response to reviewers Click here to access/download;Supplementary Material;Fusaro
et la Response to reviewers JNnov2019.docx
Reviewer #1: The new version is improved. 
Comment 1: Please note, line 300 edit ‘those’ into ‘whose’ or change the phrase.   
Thank you’. We have changed ‘those’ to ‘whose’ as highlighted in the text.  
 
 
Reviewer #2: The authors provide an overview on actions of vitamin k beyond bone and 
cardiovascular health. Now, the authors have improved the readability and the scope of the 
manuscript becomes way more clear. 
I have few comments left. 
 
Comment 1: Passage on MGP- first sentence- revised. 
I still do not agree with the phrasing. ‘MGP….after carboxylation shows 5 gamma 
carboxyglutamic acid residues’- it can show up to 5 carboxylated residues, as also explained 
later in this passage. 
Thank you for your comment. We have changed the sentence from ‘MGP is a 14 kDa vitamin K-
dependent protein which after carboxylation shows 5 gamma-carboxyglutamic acid residues’ to 
‘MGP is a 14 kDa vitamin K-dependent protein which after carboxylation can have up to 5 
gamma-carboxyglutamic acid residues’ 
 
Comment 2: Vitamin K as ligand of Nuclear Receptors 
I think the connection between vitamin D and vitamin K is highly interesting, especially as a 
passage on CKD follows. A remark on the pathology of CKD-MBD would strengthen the 
importance of this pathway. 
Thank you for this comment, indeed it’s very intriguing the connection between Vitamin D and 
Vitamin K  highlighted by an enhanced vitamin D3 effects on BGP gene expressiona and 
osteoblast precursor following supplementation MKn (see Fusaro et al, Vitamin K and bone: 
Clin Cases Miner Bone Metab 2017 - Review. PMID 29263734 Free PMC article). However, 
Vitamin D involves one aspect of CKD-MBD. Discussing the pathology of CKD-MBD only 
briefly will not be sufficient to highlight the different underlying processes and their importance.  
 
Comment 3: Periostin 
Contrary to the other VKD proteins, the passage lacks information on the carboxylation state 
of the described effects. As this is unknown, this should be stated. 
Thank you for this comment. We have added the following sentence ‘Similar to other VKDPs, 
the carboxylation of periostin is dependent on vitamin K. However, it is unknown how the 
carboxylation status of periostin influences its functions in different tissues.’ 
 
Comment 4: Conclusion 
The authors want to ‘develop techniques that can directly measure vitamin K’. Why? First, the 
technique is available- second, it just mainly reflects the short term intake of vitamin K and 
not the general vitamin K status. 
Thank you for the comment. The thechnique is available but it is not standardized. We have 
added in the sentence standardized.  
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Introduction: 49 
The vitamin K family is comprised of a group of fat-soluble molecules that share the 2-methyl-1,4-50 
naphthoquinone (3-) groups. Vitamin K exists in 3 main forms, K1 and K2 which are the natural 51 
form, and K3 or menadione which is the synthetic form of the vitamin [1]. Vitamin K1, also known 52 
as phylloquinone, is found in vegetables, while vitamin K2, also known as menaquinone, is found in 53 
fermented food or produced by the intestinal microbiota. Vitamin K1 can be converted into vitamin 54 
K2.   Two mechanisms of action of vitamin K have been described to date. It is an essential cofactor 55 
for the function of the enzyme γ‐glutamyl carboxylase, and it acts as a ligand of the steroid and 56 
xenobiotic receptor (SXR) and pregnane X receptor (PXR, murine ortholog) [2]. 57 
Vitamin K-dependent proteins (VKDPs) play important roles in human physiology and can be an 58 
important link between the bone and the vasculature. This link becomes particularly important in 59 
patients with chronic kidney disease (CKD) who have a high prevalence of both mineral bone 60 
disorders (MBD) and vascular calcification (VC) [3] and whose primary cause of death is 61 
cardiovascular disease. Osteocalcin (OCN) is a VKDP known to be involved in bone mineralization, 62 
while Matrix GLA protein (MGP) is a known VC inhibitor whose deficiency is associated with 63 
increased risk for VC in CKD. New VKDPs have been discovered, and they have been found to play 64 
important roles in various cancers and their therapies.  65 
While many questions have been answered, many more remain regarding the roles of the VKDPs in 66 
bone and vascular physiology. This review will discuss the roles of VKDPs and vitamin K in different 67 
pathologies.  68 
 69 
Vitamin K Dependent Protein (VKDPs) 70 
Vitamin K is an essential cofactor required for the activation of the gamma glutamyl carboxylase 71 
which converts glutamic acid to γ-glutamic acid residues. There are several vitamin K dependent 72 
proteins (VKDPs) [4]. These include the coagulation factors proteins C, S, M, Z, factors VII, IX, X 73 
and prothrombin. VKDPs also include Bone Gla Protein (BGP, or osteocalcin), Matrix Gla Protein 74 
(MGP), Gas6 (Growth Arrest-Specific 6 Protein), GRP (Gla Rich Protein) and Periostin. VKDPs play 75 
established roles in coagulation, in bone health and in cardiovascular health.  76 
 77 
Bone Gla Protein (BGP): Beyond Skeletal Health  78 
BGP or osteocalcin is the most abundant protein in bone. It is mainly secreted by osteoblasts, with a 79 
smaller amount secreted by chondrocytes[5]. BGP undergoes three carboxylation events to be 80 
transformed from the undercarboxylated form into the fully functional form. These carboxylation 81 
events require vitamin K as a cofactor[6]. Several mechanisms describing the BGPs role in bone 82 
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physiology have been proposed, including the inhibition of bone mineralization[7], the regulation of 83 
the rate of mineral maturation[8], and the formation of a complex between bone matrix and collagen 84 
in order to increase bone toughness[9]. However, none of these mechanisms are fully proven.  85 
 86 
More recently, the relationship between BGP and glucose metabolism has been elucidated. In this 87 
role, BGP is thought to be released into the circulation and to exert an action similar to a hormonal 88 
effect[10]. This shed light into the peripheral functions of BGP and led to increased interest in this 89 
protein, therefore uncovering a wide range of functions.  90 
 91 
The role of BGP in glucose metabolism and insulin signaling was first discovered by Lee et al[11] 92 
whose experiments showed that BGP knockout mice develop glucose intolerance, insulin resistance, 93 
and increased adipose tissue. The circulating form of BGP exerting the metabolic effects is mostly 94 
the undercarboxylated form (ucBGP). By binding to the receptor Gprc6a, in animals ucBGP acts on 95 
the pancreatic beta cells [10]. The influence of BGP on insulin sensitivity may be mediated via its 96 
effect on adiponectin, independent of insulin secretion[11]. Human studies have not shown this 97 
metabolic effect, however. When Basu et. al administered insulin to seven diabetic and seven non-98 
diabetic patients and assessed the association with bone turnover markers, the change in the insulin 99 
levels did not influence BGP and ucBGP levels[12]. In humans, BGP also acts on Leydig cells thereby 100 
affecting the reproductive function of males[13].  101 
 102 
Beyond the metabolic functions, BGP is involved in vascular calcification (VC) modulation through 103 
its effect on adiponectin[11]. Adiponectin inhibits osteoblastic differentiation of vascular smooth 104 
muscle cells, therefore protecting against VC[14]. In apolipoprotein E-deficient mice, daily injections 105 
of BGP for 12 weeks resulted in endothelium protection from atherosclerosis, but whether this was 106 
also mediated by the concomitant improvement in glucose metabolism is unknown[15]. Similarly, 107 
diabetic rats given daily injections of BGP had an improvement in arterial stiffness as assessed by 108 
pulse wave velocity[16].  109 
The role of BGP in modulating and possibly preventing VC was confirmed in humans. BGP may 110 
exert this effect through its interaction with adiponectin, as seen by Bacchetta et al. when they found 111 
a significant association between BGP and adiponectin in CKD patients[17].  112 
In human cardiovascular tissues, BGP was found in higher concentrations in calcified aorta and 113 
valves as compared to non-calcified tissue[18]. Fusaro et al. found lower BGP levels in patients with 114 
aortic and iliac calcifications as compared to patients without calcifications[19]. In men aged 51-85 115 
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years old in the MINOS study, higher total BGP levels were associated with slower progression of 116 
abdominal aortic calcification after a 10 year follow up[20].  117 
 118 
In contrast to the above findings, in the Study of Osteoporotic Fractures (SOF) which enrolled 363 119 
elderly women, total BGP levels were not associated with abdominal aortic calcification[21].  120 
Moreover, in a meta-analysis of 46 clinical studies evaluating the relationship between BGP and VC, 121 
no definite associations could be found between the different forms of BGP (ucBGP, cBGP and total 122 
BGP) and VC. However, sound physiological conclusions cannot be drawn based on these findings. 123 
In fact, 44% of the included studies did not adjust for confounding variables and the BGP forms were 124 
measured using different assays in the different studies[22]. Moreover, BGP displays a circadian 125 
rhythm with levels falling in the morning and reaching the peak in the evening [23]. Therefore, the 126 
timing of blood draws may impact the results of the studies. It is also important to note that BGP is 127 
cleared by the kidneys[24]. Therefore any decline in renal function results in an elevation in BGP 128 
levels [24]. This is particularly notable when the glomerular filtration rate drops below 20 ml/min[24] 129 
. Additionally, based on the aforementioned studies, gender appears to be a confounding factor with 130 
the effects of BGP being differential between males and females. Vitamin K levels are obvious 131 
confounders. Moreover, menopausal status, adipose tissue, diabetic status are all expected to be 132 
confounders as well [25]. If we want studies that more accurately unravel the effect of BGP on the 133 
vasculature, we should standardize our BGP serum measurements and understand more carefully the 134 
confounders that should be accounted for. 135 
 136 
Matrix Gla Protein (MGP): Beyond Cardiovascular Health  137 
MGP is a 14 kDa vitamin K-dependent protein which after carboxylation can have up to 5 gamma-138 
carboxyglutamic acid residues [26]. In addition to gamma-carboxylation, MGP requires post-139 
translational serine phosphorylation. Phosphorylation occurs at 3 serine residues via the enzyme 140 
casein kinase[26, 27]. Phosphorylation regulates the protein secretion into the extracellular 141 
environment[26]. Based on the degree of carboxylation and phosphorylation, multiple forms of MGP 142 
can be found in the circulation and the extracellular matrix (Figure 1). MGP is released from vascular 143 
smooth muscle cells and chondrocytes [28]. It was the first calcification inhibitor to be 144 
characterized[28].  The exact mechanism through which MGP inhibits VC is not completely 145 
understood. However, the carboxylated active form of MGP is believed 1) to bind to calcification 146 
crystals in blood vessels forming vesicles and apoptotic bodies, 2) to directly prevent calcium 147 
phosphate precipitation, and 3) to prevent the trans-differentiation of vascular smooth muscles cells 148 
into an osteogenic phenotype [26, 29].  149 
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The different forms of MGP can be used as a biomarker of vitamin K deficiency[30]. Vitamin K 150 
deficiency in CKD leads to a decrease in the levels of the phosphorylated-carboxylated MGP (p-151 
cMGP) and a rise in the levels of dephosphorylated undercarboxylated MGP (dp-ucMGP) [31]. 152 
Plasma dp-ucMGP levels increase as CKD advances with the highest levels found in CKD stage 153 
5[31]. Plasma dp-ucMGP is positively associated with VC and might be utilized as an early marker 154 
for vascular calcification in CKD patients[30, 31]. 155 
 156 
Beyond the well-established effects of MGP in VC[32] studies also suggest that it has a role in skeletal 157 
health. Mice deficient in MGP develop diffuse VC as well as inappropriate calcification of the growth 158 
plate[28]. Mice overexpressing Mgp in osteoblasts have a decrease in bone mineralization 159 
particularly in the tooth dentin and cementum. Thus, MGP affects bone mineralization[33]. MGP 160 
interacts with both osteoblasts and osteoclasts. Phosphate regulates MGP expression in osteoblast 161 
cultures via the ERK1/2-Fra-1 pathway [34]. Via Src/Rac1 signaling, MGP modulates 162 
osteoclastogenesis; MGP depletion favors while MGP excess inhibits osteoclast differentiation [35]. 163 
 164 
In clinical studies, homozygosity of the MGP rs1800802 minor allele, but not total serum MGP levels 165 
was associated with 0.56 times lower prevalence of hand osteoarthritis compared with having ≥ 1 166 
major allele at this locus (95% CI 0.32-0.99, p<0.05), suggesting a role for MGP in osteoarthritis[36]. 167 
Among 145 participants in the European Vertebral Osteoporosis Study, men with the homozygous 168 
MGP-7AA polymorphism had significantly more femoral bone loss as compared to those with 169 
genotypes -7GG and -7GA [37]. Those homozygous for MGP 83Ala-Ala had significantly more 170 
femoral neck loss as well as a greater tendency to vertebral fractures as compared to those with the 171 
genotypes 83Thr-Thr and 83Thr-Ala. A decrease in BMD was observed only in MGP-7AA and 172 
MGP 83Ala-Ala genotypes. These associations were not found in the 151 women who participated 173 
in the study possibly because 94% of the women were post-menopausal and had independent post-174 
menopausal bone loss that could have confounded the effect of the MGP polymorphisms.  175 
The effect of MGP on fractures and bone density was similarly seen following kidney transplantation. 176 
Evenepoel et al. evaluated vitamin K deficiency as measured by dp-ucMGPlevels in 468 de novo 177 
kidney transplant recipients. The patients with the highest tertile of dp-ucMGPlevels had lower bone 178 
mineral density and had higher incident fractures independently of common fracture determinants 179 
(HR 2.21; 95% CI, 1.00 to 4.91; p < 0.05) [38].  180 
 181 
Studies evaluating the relationship between renal clearance and MGP levels are rare. In 842 182 
outpatients with stable cardiovascular disease and a mean GFR of 76±23 mL/min, each 10 mL/ min 183 
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lower GFR was associated with a 79 nM lower ucMGP serum level (p < 0.001), and a 0.1 mg/L 184 
higher cystatin-C was associated with a 39 nM lower ucMGP serum levels (p < 0.001) in multivariate 185 
adjusted models [39]. However, when Rennenberg et al. looked at this association, they found no 186 
significant correlations between total MGP levels in renal arterial and venous blood and renal 187 
clearance of 90 patients with hypertension[40]. It is important to note however that none of the 188 
patients in this cohort had a GFR <26 mL/min[40]. A relationship between MGP levels and renal 189 
clearance at a GFR <26 mL/min is therefore still possible. 190 
 191 
 192 
Vitamin K as Ligand of Nuclear Receptors  193 
Vitamin K can act as ligand of the nuclear Steroid and Xenobiotic Receptor (SXR) and its murine 194 
ortholog, Pregnane X Receptor (PXR)[41]. SXR/PXR is present in different tissues, including 195 
osteoblastic cell lines [42, 43]. The presence of SXR/PXR in osteoblastic tissue is important as it 196 
could be the pathway through which vitamin K improves bone health [44].  197 
Transcriptome analysis has revealed a number of bone-related genes which are involved in the 198 
vitamin K-SXR pathway. These include tsukushi and matrilin-2, which are involved in collagen and 199 
extracellular matrix assembly [45, 46]. In sarcoma cells, vitamin K up-regulates osteoblastic bone 200 
markers [43]. SXR/PXR knockout mice have increased bone resorption and decreased bone 201 
formation [47]. 202 
 203 
SXR is additionally involved in bone metabolism via its effect on vitamin D metabolism. In this role, 204 
SXR activation can have two effects.  SXR activation by some drugs can lead to CYP3A4 expression 205 
(exerting 24- and 25-hydroxylase activity) and resultant vitamin D metabolism and deficiency. SXR 206 
activation can also lead to inhibition of CYP24A1 (24-hydroxylase activity) in the kidney therefore 207 
increasing 1,25(OH)D levels [48]. These data suggest that SXR/PXR is another pathway through 208 
which vitamin K is involved in bone homeostasis. 209 
 210 
Vitamin K in Chronic Kidney Disease (CKD) 211 
The western diet does not provide enough vitamin K to activate VKDPs in all tissues[49]. This 212 
deficiency is more pronounced in adults over the age of 40. Patients with CKD have even greater 213 
rates of vitamin K deficiency as compared to the general population. The number of CKD patients 214 
who have vitamin K deficiency reaches 70-90% of that population [50, 51, 52] (Table 1). Poor oral 215 
intake of vitamin K is the main cause of deficiency [50, 53]. When compared to healthy individuals, 216 
the vitamin K intake of HD patients is particularly low on days of dialysis and the weekend[54]. The 217 
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use of phosphorus binders in the dialysis population contributes to vitamin K deficiency as well [55]. 218 
Being lipophilic, vitamin K should not be removed via dialysis. However, studies to validate this 219 
hypothesis are needed, because serum levels of 25(OH)-vitamin D, another lipophilic molecule, 220 
decreased in patients who were switched from conventional hemodialysis to online hemodiafiltration 221 
[56]. 222 
 223 
There are known implications of vitamin K deficiency in population-based studies and in kidney 224 
disease patients [57, 58]. In the Rotterdam study of 7983 men and women over the age of 55, intake 225 
of menaquinone protected against incident coronary heart disease (RR of highest tertile of 226 
menaquinone intake as compared to lowest tertile = 0.59, p=0.007), and against coronary heart disease 227 
related mortality (RR of highest tertile of menaquinone intake as compared to lowest tertile = 0.43, 228 
p=0.005). Additionally, the odds ratio of severe aortic calcification was significantly lower in the 229 
patients with the highest intake of menaquinone intake as compared to those with lowest intake (OR 230 
0.48, p <0.001) [59]. In the VIKI study, a cohort of 387 dialysis patients, 35.4% of patients had 231 
menaquinone-7 deficiency, 23.5% of patients had vitamin K1 deficiency and 14.5% of patients had 232 
menquinone-4 deficiency [57]. Patients with menaquinone-4 deficiency had significantly higher 233 
aortic calcification (10.6% versus 1.3%, p = 0.01). Menaquinone-7 deficiency was associated with 234 
significantly higher iliac calcifications (41% versus 28.2%, p = 0.009) [57]. 235 
 236 
There is no gold-standard for the measurement of vitamin K levels and there is a lack in 237 
standardization. Instead, functional deficiency of vitamin K is used as a surrogate of vitamin K status 238 
in individuals. Vitamin K deficiency in CKD leads to a decrease in the levels of active MGP, a rise 239 
in the levels of dp-ucMGP, as well as a rise in the levels of ucBGP[37]. Plasma dp-ucMGP levels 240 
increase as CKD advances with highest levels being in CKD stage 5[38].  A dp-ucMGP level of >500 241 
pmol/L, ucBGP>4.5 ng/mL[59] or protein induced by vitamin K absence-II (PIVKA-II) >2 nM/L  242 
are indicative of vitamin K deficiency [30, 60].  243 
 244 
In 53 dialysis patients, vitamin K2 supplementation resulted in a dose dependent decrease in 245 
functional vitamin K deficiency. After a 6-week supplementation regimen, dp-ucMGP levels were 246 
reduced 77% and 93% in the groups receiving daily oral administration of 135 μg and 360 μg of K2, 247 
respectively[61]. In 200 HD patients receiving vitamin K2 at dose of 360, 720 or 1080 µg thrice 248 
weekly for 8 weeks, dp-uc-MGP levels decreased by 17%, 33% and 46% respectively[62]. Several 249 
studies show the same pattern (Table 2). 250 
 251 
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Although kidney transplantation is associated with an improvement in vitamin K levels[55],  a 252 
deficiency in vitamin K was still found in up to 91% of kidney transplant patients.  This deficiency 253 
may persist as long as 188 months post transplantation[38, 63]. Moreover, in at least one study, 254 
vitamin K deficiency in kidney transplant patients was associated with an almost 3 times increase in 255 
all-cause mortality [63]. 256 
 257 
How Current therapy of MBD in CKD Influences Vitamin K levels and VKDPs 258 
While MBD derangements contribute to renal osteodystrophy and to VC in CKD [64], treatments of 259 
MBD have not been sufficiently successful at reversing VC, improving cardiovascular events or 260 
decreasing mortality. We hypothesize that this might be partly explained by the negative impact of 261 
some of the MBD treatments on vitamin K levels. One such treatment is sevelamer. Sevelamer is 262 
thought to bind fat-soluble vitamins [65, 66]. Since vitamin K is a fat-soluble vitamin, Jansz et al. 263 
assessed the impact of sevelamer on vitamin K in patients who received a kidney transplantation. 264 
They found that sevelamer is associated with higher dpu-cMGP levels reflecting vitamin K deficiency 265 
[55]. This finding points to the possible need of giving vitamin K supplements to patients treated with 266 
sevelamer, but this approach should first be substantiated by a specific study. 267 
 268 
However, some MBD treatments are associated with improvements in VKDPs. In an analysis of the 269 
VIKI study [57], the use of calcimimetics and vitamin D analogs was associated with higher levels 270 
of BGP. Calcimimetic use was also associated with higher levels of total MGP [19]. Therefore, this 271 
data suggests that calcimimetics and vitamin D analogs can help preserve or improve the activity of 272 
VKDPs. 273 
 274 
VKDPs Beyond Bone and Vascular Health  275 
 276 
Growth Arrest-Specific Protein 6 (Gas6) 277 
Gas6 is a gamma-carboxyglutamic acid (Gla) domain-containing protein, member of the VKDPs 278 
family, which is present in several different tissues (e.g. vascular endothelium, kidney, heart, and the 279 
bone marrow). It is a ligand for the TAM (Tyro3-Axl-Mer) receptor family [67] and is thought to be 280 
involved in the stimulation of cell proliferation, migration and apoptosis [68, 69]. 281 
Gas6 and protein S are two homologous secreted proteins depending on vitamin K for a wide range 282 
of their biological functions. A discrete subset of these functions is mediated through their binding to 283 
and activation of the receptor tyrosine kinases Axl, Sky and Mer; in particular, the vitamin K-284 
dependent protein Gas6 activates receptor tyrosine kinases of the Axl family [69].  285 
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A hallmark of the Gas6-Axl system is the unique ability of both Gas6 and protein S to tether their 286 
non receptor-binding regions to the negatively charged membranes of apoptotic cells. A relevant 287 
amount of evidence suggests that the Gas6-Axl system is able to regulate cell survival, proliferation, 288 
migration, adhesion and phagocytosis. Consequently, an altered expression, or a compromised 289 
activity of its components have been detected in a variety of diseases, including different cancer types. 290 
Moreover, Axl overactivation can equally occur without ligand binding, which has implications for 291 
tumorigenesis. [70] 292 
Upregulation of Gas6 has been described in different malignancies [71], and an increased expression 293 
of either Gas6 or TAM receptor proved to be predictive of poor prognosis[72]. A number of animal 294 
studies highlighted the role of Gas6 in the processes of carcinogenesis [71, 72, 73], while clinical 295 
studies are rarer, but ultimately show consistent findings. Ovarian cancer samples from 90 patients 296 
had significantly higher expression of Gas6 and Axl as compared to normal ovarian tissue [73], RNA 297 
PCR from 42 glioblastoma frozen sections demonstrated that Gas6 and Axl are overexpressed both 298 
in the tumoral, as well as in the surrounding vascular, tissue [74]. Furthermore, glioblastoma patients 299 
whose tumors expressed higher Gas6 and Axl levels had significantly higher risk of tumor relapse as 300 
well as shorter time to relapse [74]. A similar observation has been reported in osteosarcoma; indeed, 301 
in 62 osteosarcoma patients, Axl was highly expressed in 43.5% of the cases, characterized by a 302 
significantly higher rate of recurrence, lung metastases, as well as a lower survival [75]. Gas6-Axl is 303 
also important as mechanisms of resistance to anticancer therapy; indeed, resistance to tyrosine kinase 304 
inhibitors in non-small cell cancer and renal cell carcinoma (RCC) was found to be driven by Axl 305 
[76].  306 
As far as RCC, the Axl protein proved to be highly expressed in clear cell RCC cells deficient in 307 
functional von Hippel-Lindau (VHL) protein, a tumor suppressor gene often inactivated in ccRCC. 308 
VHL reconstituted cells expressed decreased levels of Axl protein, but not Axl mRNA, suggesting 309 
that VHL may regulate Axl expression. Furthermore, Gas6-mediated activation of Axl in ccRCC cells 310 
resulted in Axl phosphorylation, receptor down-regulation, decreased cell-viability, as well as 311 
migratory capacity, whilst no effects of the Gas6/Axl system could be detected on invasion. 312 
Moreover, in ccRCC tumor tissues, Axl was phosphorylated and Gas6 gamma-carboxylated, 313 
suggesting these molecules to be active in vivo. [77] 314 
All the above has practical therapeutic implications, as targeting the Gas6-Axl pathway through the 315 
multikinase inhibitor cabozantinib proved to be an active treatment option for metastatic RCC 316 
patients progressing on standard antiangiogenic therapy [78].   317 
 318 
Periostin 319 
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Periostin is another member of the VKDP family. Similar to other VKDPs, the carboxylation of 320 
periostin is dependent on vitamin K. However, it is unknown how the carboxylation status of periostin 321 
influences its functions in different tissues. Periostin is an extracellular matrix protein that binds 322 
integrins playing a role in cellular adhesion and migration[79]. It plays a role in collagen assembly in 323 
several tissues and is upregulated when tissues are subjected to stress[79-81]. Following cardiac 324 
injury, periostin is expressed in cardiac myofibroblasts and vascular smooth muscle cells contributing 325 
to a profibrotic phenotype[81-83]. Similar to other VKDPs, periostin has also been found in many 326 
cancers [84-86]. Periostin induces tumor angiogenesis[84, 85] and lymphangiogenesis [85], and its 327 
association with cancer confers a worse prognosis to patients[85]. The role of periostin in breast 328 
cancer has been described. Periostin is expressed in invasive ductal carcinoma cells [87]. Its 329 
expression increases with the cancer grade, suggesting that periostin may play a role in cancer 330 
progression[88]. Periostin can also serve as marker of breast cancer metastasis. Human breast cancer 331 
exosomes contain periostin. Further, periostin enriched exosomes were found in patients with lymph 332 
node metastasis as compared to those with localized disease[89]. Finally, periostin may have a role 333 
in breast cancer prognostication. In 259 breast cancer patients who underwent surgical and radiation 334 
therapy, local recurrence-free survival, distant metastasis-free survival and overall survival were 335 
significantly lower in the patients whose tumors expressed periostin as compared to those whose 336 
tumors were negative for periostin [90].  337 
 338 
 339 
Gla-Rich Protein (GRP) 340 
 341 
GRP is one of the newest members of the VKDP family. Its name derives from the large amount of 342 
Gla residues, which comprise 22% of its composition[91], and which make it the VKDP with the 343 
highest concentration of Gla residues. Since its discovery, GRP has been found to have a role as an 344 
anti-inflammatory protein[92]. In vivo, it prevents osteoarthritis progression[93]. It additionally plays 345 
a role in mineralization. In both animal models and in humans, GRP has been found to colocalize 346 
with mineral deposits at sites of calcification[94]. Further work demonstrates that similar to MGP, 347 
GRP in its carboxylated but not in its undercarboxylated form is a calcification inhibitor [95]. 348 
Although GRP role in cancer is less established as compared to other VKDPs, there is growing 349 
interest surrounding this protein. The undercarboxylated form as compared to the carboxylated form 350 
of GRP is found in more abundance in skin and breast cancer cells, particularly in microcalcifications 351 
associated with these tumors [96]. Therefore, GRP may be involved in cancer-related calcifications 352 
and as such may prove to be a therapeutic target for some types of cancer. 353 
 354 
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Vitamin K in Cancer 355 
Several VKDPs are involved in tumorigenesis[71, 84, 85] (Table 3). Vitamin K2 administration in 356 
vivo inhibits the cellular proliferation of several cancers [96, 97]. This led to a number of studies 357 
investigating the role of vitamin K intake and supplementation in preventing cancer development, 358 
progression and recurrence. In the European Prospective Investigation into  359 
Cancer and Nutrition-Heidelberg cohort study which included 24,340 cancer-free participants 360 
followed up for 10 years, there was a significant  inverse association between vitamin K2 intake and 361 
cancer mortality, but not cancer incidence[98]. Similarly, in the Prevención con Dieta Mediterránea 362 
study, which enrolled 7216 participants followed up for a median of 4.8 years, subjects who increased 363 
their dietary intake of both vitamin K1 and K2 had decreased cancer incidence[99].  364 
The undercarboxylated form of prothrombin (PIVKAII), a VKDP, is upregulated in hepatocellular 365 
carcinoma (HCC) [100]. Vitamin K2 supplementation in patients who underwent curative 366 
hepatectomy or radiofrequency ablation for HCC suppressed HCC recurrence, though this effect 367 
did not reach statistical significance in any of these studies[101, 102]. In contrast, 45 mg per day 368 
of vitamin K2 supplementation resulted in significantly lower risk of HCC development in 21 369 
women who had viral cirrhosis as compared to 19 women with viral cirrhosis who did not receive 370 
supplementation[103]. This suggests that vitamin K2 may play a role in preventing the development 371 
of HCC in high risk patients. Overall, the association and the relationship of vitamin K with cancer 372 
is still uncertain and under investigation. Further studies are needed to define this role of vitamin 373 
K. 374 
 375 
Conclusion  376 
Substantial research has made it clear that VKDPs or Vitamin-K related pathways can be used in the 377 
future to diagnose, treat and prognosticate a number of health conditions. There are still more vitamin 378 
K-related roles to be uncovered and which will further our understanding of the physiological and 379 
pathological importance of vitamin K status. It will also prove important to recognize the differential 380 
actions of vitamin K1 and vitamin K2, and to develop standardized techniques that can directly 381 
measure vitamin K levels instead of our current reliance on functional vitamin K status as measured 382 
by VKDPs levels [104]. This will allow to develop trials that can evaluate selective and optimal 383 
vitamin K supplementation strategies in order to further understand their effect on clinical outcomes. 384 
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TABLES AND FIGURES 654 
Table 1. Vitamin K and VKDP levels in Kidney Disease 655 
AUTHOR, YEAR NUMBER OF 
PARTICIPANTS 
KIDNEY 
DISEASE 
STAGE 
VITAMIN K FORM 
MEASURED 
% OF 
PATIENTS 
WITH 
VITAMIN K 
DEFICIENCY   
VKDP 
MEASURED 
% OF 
PATIENTS 
WITH 
MEASURED 
VKDP  
Kolheimer M., 
1997 [105] 
68 ESKD -HD Phylloquinone 33%  
 
  
Pilkey RM., 2007 
[106]  
142 ESKD Phylloquinone 29% ucBGP 93% 
Holden RM, 2008 
[52] 
21 ESKD- PD Phylloquinone 
 
24% 
 
ucBGP 60% 
Holden RM, 2010 
[107] 
172 CKD 3-5 Phylloquinone 
 
6% 
 
 
ucBGP 
 
PIVKAII 
60% 
 
97% 
Schurgers LJ, 2010 
[108] 
107 CK2-5 and 
ESKD-HD 
  dp-ucMGP 50% 
Schlieper G, 2011 
[109] 
188 ESKD-HD   PIVKA-II 
 
dp-ucMGP 
63% 
 
100% 
Cranenburg EC, 
2012 [54] 
40 ESKD-HD Phylloquinone 
 
Menaquinone 
45% 
 
100% 
PIVKAII 
 
dp-ucMGP 
82.5% 
 
100% 
Westendfeld R, 
2012 [61] 
53 ESKD-HD Menaquinone 100% PIVKAII 
 
dp-ucMGP 
92.5% 
 
100% 
Fusaro M, 2012 
[57] 
387 ESKD-HD Phylloquinone 
 
Menaquinone-4 
 
Menaquinone-7 
23.5% 
 
14.5% 
 
35.4% 
ucBGP 
 
100% 
Boxma PY, 2012 
[110] 
60 Post-
Transplantation 
  dp-ucMGP 80% 
Caluwe R, 2013 
[62] 
165 ESKD-HD   dp-ucMGP 100% 
Delanaye P, 2014 
[111] 
160 ESKD-HD   dp-ucMGP 100% 
 CA, 2015 [63] 518 Post-
Transplantation 
  dp-ucMGP 91% 
Aoun M, 2017 
[112] 
50 ESKD-HD   dp-ucMGP 100% 
 656 
 657 
 658 
  659 
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Table 2. Effect of Vitamin K supplementation on dephosphorylated-undercarboxylated MGP 660 
levels in ESKD  661 
AUTHOR, 
YEAR 
STUDY 
DESIGN 
NUMBER OF 
PARTICIPANTS 
KIDNEY 
DISEASE 
STAGE 
INTERVENTION OUTCOMES 
MEASURED 
RESULTS 
Schlieper 
G., 2011 
[109] 
Prospective 17 ESKD Vitamin K2 at 
135 μg/d for 6 
weeks 
dp-ucMGP 
level 
 Vitamin K2 supplementation resulted in a 
27% reduction in dp-ucMGP levels  
p = 0.0027 
Westenfeld 
R., 2012 
[61] 
Prospective 53 ESKD Vitamin K2 at 45, 
135, or 360 μg/d 
for 6 weeks 
dp-ucMGP 
level 
Vitamin K2 supplementation resulted in a 
dose-dependent decrease in the levels of 
dp-uc-MGP by 17.9%, 36.7%, and  
61.1% in the 45-, 135-, and 360-μg  
groups, respectively, compared with  
baseline values. p<0.005 
Caluwe R, 
2014 [62] 
Prospective 200 ESKD Vitamin K2 at 60, 
720 or 1080 µg 
thrice weekly for 
8 weeks  
  
dp-uc-MGP 
level 
  
  
Vitamin K2 resulted in a dose-dependent 
decrease in the levels of dp-uc-MGP by 
17%, 33% and 46% in the 360-, 720- and  
1080-µg groups, respectively, compared to 
baseline values.  p < 0.001 
Aoun M, 
2017 [112] 
Prospective 50 ESKD 360 μg of vitamin 
K2 
(menaquinone-7) 
for 4 weeks 
dp-uc-MGP 
level 
Vitamin K2 reduced dp-ucMGP by 86% 
P<0.05 
 662 
Table 3. Effects of VKDPs on cancer development and progression. 663 
  664 
Vitamin K dependent proteins activity may modulate cancer behavior 
Gas 6 • Angiogenesis 
• Tumor Progression 
• Higher Tumor Recurrence 
• Metastasis and Poorer Prognosis 
• Cancer Therapy Resistance 
Periostin • Angiogenesis 
• Lymphangiogenesis 
• Tumor Progression 
• Poorer Prognosis 
PIVKAII • Tumor Progression 
 665 
 666 
 667 
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Figure legends 668 
Figure 1. Different Forms of matrix Gla protein (MGP). 669 
 670 
 671 
 672 
